Health1 min read

STAT+: Flagship opens biotech-creation outpost in the U.K.

By · Via STAT Health · Published by Everything Blog

In short

Recent momentum across the life sciences ecosystem spans international enterprise building, massive artificial intelligence financing, and oncology trial progress. While venture creation platforms broaden their geographical reach, AI drug developer Isomorphic Labs bolstered its balance sheet by closing a $5 billion private financing round. Meanwhile, Sellas Life Sciences posted positive data for an experimental blood cancer immunotherapy. This candidate achieved a 41% reduction in the risk of death compared to standard care for patients diagnosed with advanced acute myeloid leukemia.

Key points

  • Global venture creators are actively broadening their operational footprints to launch no…: Global venture creators are actively broadening their operational footprints to launch novel life sciences enterprises abroad.
  • Large-scale private funding rounds continue to flow directly into artificial intelligence…: Large-scale private funding rounds continue to flow directly into artificial intelligence drug development platforms.
  • Emerging blood cancer therapies are demonstrating significant clinical potential to impro…: Emerging blood cancer therapies are demonstrating significant clinical potential to improve survival outcomes over existing care standards.

Sources checked by our analysis pipeline: 1

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. We’ve got a lot of news to get into today, including some big developments in oncology.

The need-to-know this morning

- Isomorphic Labs, the AI drug developer, raised $5 billion in private financing.

Sellas’ blood cancer immunotherapy cut risk of death

An experimental drug from Sellas Life Sciences reduced the risk of death by 41% compared to standard treatment for patients with an advanced stage of acute myeloid leukemia, the company said this morning.

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Health